PTO/SB/08s (08-03)
Approved for use through 97/31/2006, 0NE 0851-0331
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number	- 1	
	Filing Date		
	First Named Inventor	in KEUPP	
	Art Unit	$\Box$	
	Examiner Name		
	Attorney Docket Number	Т	PHUS030454US

					U.S.	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	Date	Name of Patentee or Applicant R		Releva		Lines where ges or Relev	
	1	6552540	B2	2003-04	4-22	Fuderer		all			
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	tion	of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	20020021128	A1	2002-02	2-21	Kuhara		all			
	2	20030004408	A1	2003-01	1-02	Zhu		all			
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	olease click the Ad	d button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date Name of Patentee Applicant of cited Document		e or  v	here Rel	or Relevant	т
	1	EP 1 398 642	EP		A2	2004-03-17	General Electric		BII		
	2	WO2004/077096	wo		A1	2004-09-10	KPENV		ıll		

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Fili

Ex

Application Number		
Filing Date		
First Named Inventor	Joch	ien KEUPP
Art Unit		
Examiner Name		
Attorney Docket Numb	er	PHUS030454US

ii you wisi	ii to a	d additional Poleign Patent Document dission information please dick the Add button			
		NON-PATENT LITERATURE DOCUMENTS Remove			
Examiner Initials*					
	1	KEUPP, J., et al.; Continuous Moving Table SENSE Imaging; 2004; Proc. Intl. Soc. Mag. Reson. Med.; 11:324.			
	2	KRUGER, D.G., et al.; Continuously Moving Table Data Acquisition Method for Long FOV Contrast-Enhanced MRA and Whole-Body MRI; 2002; MRM; 47:24-231.			
	3	MCKENZIE, C.A., et al.; Selfi-Calibrating Parallel Imaging with Automatic Coll Sensitivity Extraction; 2002; MRM; 47.529-538.			
	4	POLZIN, J.A., et al.; Correction for Gradient Field Distortions in Moving Table Imaging; 2002; Proc. Intl. Soc. Mag. Reson. Med.; 10 abstract.			
	5	PRUESSMANN, K.P., et al.; SENSE: Sensitivity Encoding for Fast MRI; 1999; MRM; 42:952-962.			
	6	SHETTY, A.N., et al.; Lower Extremity MR Angiography. Universal Retrofiting of High-Field-Strength Systems with Stepping Kinematic Imaging Platforms-Initial Expenence; 2002; Radiology; 222(1):84-291.			
	7	ZHU, Y.; FUSION for incremental Field-of-View imaging, 2001; Proc. Intl. Soc. Mag. Reson. Med.; 9.9.			
If you wis	h to a	d additional non-patent literature document citation information please click the Add button Add			
		EXAMINER SIGNATURE			
Examiner	Signa	ure Date Considered			
*EXAMIN	ER: Ir	tial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a			

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application Number			
INFORMATION DIGGS COURT	Filing Date			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Joch		en KEUPP	
	Art Unit			
	Examiner Name			
	Attorney Docket Number	r	PHUS030454US	

See Mark Codes of USPTO Palent Documents at year, USPTO DOLY or METP P010.4. Faster office in all assest the document, by the lost-letter code (WPO) Standard ST(3), 3" For Legislance splant of comments, the indication of the year of the region of the Engener pears for school the seal number of the palent document, "fend of document by the appropriate symbols as indicated on the document under WEPO Standard ST(16 if possible." Applicant is to place a check mark here if implies larguage strandation a statistical or

# Application Number Filing Date Filing Date

### CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make	the appropriate	selection(s):
---------------	----------	------------------	-----------------	---------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

## OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/TML/	Date (YYYY-MM-DD)	2006-05-12
Name/Print	Thomas M. Lundin	Registration Number	48979

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

# Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.